Cooperative Agreement U24CA294203
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$873K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Cooperative Agreement
Place of Performance
Boston, MA 02215, USA
Similar Awards
The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research federal grant program (CFDA 93.393), awarded a $942,442 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to identify the mechanisms driving rapid evolution of cancer genomes. The key objectives are to understand the processes of chromothripsis, a catastrophic mutational event involving massive chromosome rearrangement, and chromoplexy, another poorly understood catastrophic mutational process common...
The National Cancer Institute (NCI) awarded a $846,735 Cooperative Agreement (CFDA 93.396 - Cancer Biology Research) to the Research Foundation of the City University of New York (RFCUNY) from July 1, 2024 to June 30, 2029. The grant supports the maintenance and expansion of the Bioconductor software infrastructure to address challenges in cancer genomics research, including enhancing capabilities for multimodal experiments, spatial transcriptomics, and federated data sharing. Key objectives...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will provide $720,252 to the Dana-Farber Cancer Institute (DFCI) from April 1, 2025 to March 31, 2030 to characterize the genetic risk of cancer across diverse populations. The key products and services to be delivered include: Identifying chromatin quantitative trait loci (cQTLs) that confer risk of prostate cancer in men of African ancestry by...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The goal of this 1-year project is to develop a novel nanopore-based sequencing approach that can accurately characterize repetitive DNA sequences, which are critical for understanding cancer progression but challenging to analyze using current sequencing...
This $330,543.28 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, was awarded under the Cancer Research Manpower federal grant program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. for the period of August 16, 2021 through March 31, 2022. The grant funds research aimed at developing a pan-cancer atlas of driver mutations in over 100,000 patients through a hypothesis-driven combined computational and experimental approach....
The National Cancer Institute (NCI) awarded The Broad Institute, Inc. (Broad Institute) a $417,586 Project Grant (CFDA 93.396 Cancer Biology Research) to develop a robust, multi-omic spatial genomics platform for profiling human tumors. The project aims to extend the Broad Institute's recent invention, Slide-Tags, to enable facile, spatial profiling of a broad range of tumor specimens and measure transcription, epigenetic states, and genome variation within individual cells in the tumor...
This Project Grant award from the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351) provides $1,035,125.00 to the Dana-Farber Cancer Institute (DFCI) in Boston, MA. The funding will be used to acquire a NovaSeq X Plus high-throughput DNA sequencing system manufactured by Illumina. This new instrument will expand the capabilities of DFCI's existing Molecular Biology Core Facilities, allowing for cost-effective and rapid turnaround of whole genome...
The National Cancer Institute (NCI) awarded a $902,046 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Data Driven Bioscience Inc. for the development and validation of their DuoSeq technology. DuoSeq is a novel clinical approach that provides comprehensive molecular profiling of blood cancers from a single workflow, including DNA mutations, copy number alterations, translocations, and gene expression data. This Phase I project will perform the analytical...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
This Cooperative Agreement award, funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, aims to develop an Integrative Analysis and Visualization Platform for Cancer Regulatory Genomics. The University of Massachusetts Medical School (UMass Medical) will receive $416,745 from August 2024 to July 2027 to create a regulatory-element-target-gene atlas, identify genetic aberrations that affect regulatory elements, and establish a...